MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on January 3, 2005; DOI: 10.1124/mol.104.006130


0026-895X/05/6704-1247-1256$20.00
Mol Pharmacol 67:1247-1256, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.006130v1
67/4/1247    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bonzo, J. A.
Right arrow Articles by Tukey, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bonzo, J. A.
Right arrow Articles by Tukey, R. H.
Original Article

Arsenite Inhibition of CYP1A1 Induction by 2,3,7,8-Tetrachlorodibenzo-p-dioxin Is Independent of Cell Cycle Arrest

Jessica A. Bonzo, Shujuan Chen, Alema Galijatovic, and Robert H. Tukey

Laboratory of Environmental Toxicology, Departments of Pharmacology, Chemistry & Biochemistry, University of California, San Diego, La Jolla, California

Abstract

We show here that arsenite (As3+) elicits multiple effects on gene control, such as the interruption of cell cycle control by initiating G2/M arrest as well as inhibiting the aryl hydrocarbon (Ah) receptor-mediated 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-inducible expression of CYP1A1. This raises the question as to whether As3+ is selectively inhibiting TCDD induction of CYP1A1 independent of cell cycle control. As3+ stimulated a concentration-dependent increase in G2/M phase arrest that was detected at 12.5 µM As3. However, cotreatment of HepG2 cells with TCDD and concentrations of As3+ as low as 0.5 µM stimulated a pronounced decrease in the induction of CYP1A1-dependent ethoxyresorufin-O-deethylase activity and protein, indicating that the inhibition of CYP1A1 induction by As3+ was considerably more sensitive than As3+-initiated cell cycle arrest. Low concentrations of As3+ also initiate a dose-dependent reduction in TCDD-induced mouse Cyp1a1 as well as human CYP1A1 in primary hepatocytes cultured from transgenic CYP1A1N+/- mice. Because primary hepatocytes in culture are quiescent, these results indicate that the actions of As3+ on TCDD-initiated induction of CYP1A1 are independent of cell cycle control. As3+ does not impact on Ah receptor function as evaluated by nuclear transport and binding to xenobiotic responsive element sequences, but it does reduce TCDD-induced CYP1A1 mRNA, a property that is concordant with RNA polymerase II association to the gene and the reduction in transcriptional heteronuclear RNA. We conclude from these studies that interruption of CYP1A1-induced transcription by As3+ is not dependent upon cell cycle arrest.


Received August 12, 2004; accepted December 28, 2004

Address correspondence to: Dr. Robert H. Tukey, Leichtag Biomedical Research Bldg., Room 211, University of California, San Diego, La Jolla, CA 92093-0722. E-mail: rtukey{at}ucsd.edu







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics